Daiichi Sankyo and AstraZeneca start phase 3 urothelial cancer trial

August 26, 2026 7:00 AM

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found